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ABSTRACT

KNOCKOUT OF SPHINGOSINE KINASE 1 ATTENUATES RENAL INTERSTITIAL
FIBROSIS IN UNILATERAL URETERAL OBSTRUCTION (UUO) MODEL

By Xiwen Zhang, B.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University

Virginia Commonwealth University, 2017

Major Director: Ningjun Li, MD, Associate Professor, Pharmacology and Toxicology

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite and an important
signaling molecule that plays a significant role in the differentiation of fibroblasts to
myofibroblasts, which is seen as a crucial process during fibrogenesis. S1P synthesis is
catalyzed by sphingosine kinases (SphKs), which phosphorylate sphingosine into S1P.

xi
The present study tested the hypothesis that SphK1-S1P signaling pathway participates
in the kidney damage in unilateral ureteral obstruction (UUO) model using SphK1
knockout mice. UUO was created by ligation of the ureter on one kidney and the
unobstructed contralateral kidney is used as control. Wild type C57BL6 mice and SphK1
KO mice were subjected to UUO for 7 days or 14 days and then four groups of kidneys
were collected: wild type control group (WT-C), wild type UUO group (WT-UUO), SphK1/-

control group (KO-C) and SphK1-/- UUO group (KO-UUO). The mRNA level of SphK1

in WT-UUO was increased by 6.1 folds compared to control groups and there was no
significant difference between the other three groups. The markers of fibrosis, α-smooth
muscle actin (α-SMA) and collagen I, were both upregulated in UUO groups, whereas the
levels of these two proteins were significant lower in KO-UUO than that WT-UUO. The
immunohistochemistry analyses showed that the positive staining of α-SMA and collagen
was located in the interstitial space and the infiltration of immune cells normalized with
the WT-C, CD43- and CD68- positive cells were higher in UUO groups than in control
groups, but there was no significant difference between KO-UUO and WT-UUO. This
suggests that the differences of renal fibrotic markers between WT-UUO and KO-UUO
are not due to the change of immune regulation by knockout of SphK1, rather, it is the
direct effect of the deficiency of SphK1 on kidney tissue. Further, the morphological
examination showed that the tubular injury score and glomerular damage index were
much higher in UUO groups, but the kidney damage indices were significantly decreased
in KO-UUO compared with WT-UUO. These results suggest that SphK1-S1P signaling
pathway mediates kidney damage in UUO mice. Manipulating SphK1-S1P signaling
pathway may be used as a therapeutic strategy in renal interstitial fibrosis.

CHAPTER ONE
INTRODUCTION

1.1 Introduction of S1P
Sphingolipids, compounds that contain a long-chain sphingoid base [1], have gained
considerable attention during the last decades since they not only serve as structural
components of cell membrane but also elicit important functions as signaling molecules,
which regulate biological functions in both intracellular and extracellular compartments.
The kidney is an important tissue serving for sphingolipids studies because of the unique
wide expression of glycosphingolipids. Glycophingolipids are ceramides with one or more
sugar residues joined in a β-glycosidic linkage at the 1-hydroxyl position [2]. S1P is
produced by sphingosine kinases that phosphorylate sphingosine and is now recognized
as a critical regulator of physiological and pathophysiological processes, including
atherosclerosis, respiratory distress, diabetes, cancer and inflammatory disorders [3-6].
It also participates in diverse cellular behaviors such as cell adhesion, migration,
proliferation and differentiation. S1P targets five G-protein-coupled receptors named
S1PR1-5, which are distributed in different tissues and organs. In addition, coexpression
of S1P receptors and promiscuous coupling generates variable and complex signals [7].
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1.1.1 Metabolism of Sphingolipids
Sphingosine-1-phosphate (S1P) was originally considered as an intermediate product
during the detoxification of sphingosine. S1P synthesis is catalyzed by sphingosine
kinases. Nowadays, two isozymes of sphingosine kinases, known as SphK1 and SphK2
[8] have been identified, which catalyze the phosphorylation of D-erythro-sphingosine and
produce S1P, using ATP as phosphate donor. S1P can be converted back to sphingosine
by S1P phosphatases (SPP1 and SPP2) [9] located in the endoplasmic reticulum (ER) or
lipid phosphate phosphatases (LPP1-LPP3)
existing on the plasma membrane [10]. S1P is
further degraded by S1P lyase (SPL) into
ethanolamine phosphate and hexadecenal [11],
which is also located in the ER. The immediate
substrate

for

the

generation

of

S1P,

sphingosine, is formed from the hydrolysis of
ceramide

by

ceramidase

and

most

of

sphingosine is synthesized from this salvaged
pathway by the deacylation of ceramide [12, 13].
Ceramide is the central building block of all
sphingolipids and its de novo synthesis is from
the condensation of amino acid L-serine and

Figure 1. Biosynthesis of S1P
pathway

palmitoyl-CoA in the ER. In the catabolic pathway, ceramide is released from hydrolysis
of sphingomyelin by sphingomyelinases that is located in the cell membrane [14], which
is a more rapid way to generate ceramide than de novo synthesis pathway. Meanwhile,
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ceramide can be converted back to sphingomyelin via transferring phosphocholine from
phosphatidylcholine to ceramide, which is catalyzed by sphingomyelin synthase [1].
Figure 1 shows the general pathway of sphingolipids syntheses and metabolites [15].
The conversion among ceramide, sphingosine and S1P serves as ‘sphingolipid rheostat’
and the modulation of this ‘sphingolipid rheostat’ plays roles in cell fate determination as
well as the progression and drug sensitivity of cancer, and may act as treatment strategies
against cancer [16]. There is a concentration gradient among these three metabolites,
with ceramide presenting the highest and S1P the lowest level. A small change in
ceramide concentration significantly affects the concentration of sphingosine and S1P.
Therefore, the generation of S1P is not only regulated by biosynthetic and degradative
enzymes but also by availability of the upstream substrates.

1.1.2 Intracellular and extracellular S1P
S1P is synthesized intracellularly and then acts as a bioactive molecule in intracellular or
extracellular pathways. As an extracellular bioactive molecule, cytosolic S1P synthesis is
catalyzed by SphK1 [17]. Once S1P is formed in cytosol, it will be exported out of the cell
by several transporters including the ATP-binding cassette transporters: ABCA, ABCC1,
ABCG2 [18, 19], and the putative transporter Spinster 2 [20]. The extracellular S1P
targets its receptors on the plasma membrane to mediate extracellular signaling
pathways. Most of S1P in circulatory system of body is bound to acceptor plasma
proteins. The majority of these plasma proteins are high-density lipoprotein (HDL) and
albumin [21-23]. The effects of S1P are mostly mediated by its cell surface receptors.
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However, there is evidence, though limited, showing that S1P may also act as an
intracellular messenger. It has been demonstrated that S1P produced by SphK2 on the
ER membrane [24] mediates intracellular pathway, which plays a crucial role in
counteracting apoptosis. In addition to apoptosis [25], S1P as a second messenger in the
cell also activates calcium channels, regulates inflammatory responses, promotes cell
survival, and reduces tumor progression and size etc., though no direct intracellular target
for S1P has been found [26].

1.1.3 S1P receptors
To date, there are five specific subtypes of S1P G-protein-coupled receptors identified:
S1PR1/EDG1, S1PR2/EDG5, S1PR3/EDG3, S1PR4/EDG6, and S1PR5/EDG8, which
are coupled with various G-proteins. These G-proteins regulate different downstream
molecules of signaling pathways, such as adenylyl cyclase (AC), cyclic AMP (cAMP),
extracellular signal-regulated kinase (ERK), phospholipase C (PLC), phosphatidylinositol
3-kinase (PI3K), the small GTPases of the Rho family and Jun amino terminal kinase
(JNK) etc. [27, 28]. Like other G-protein-coupled receptors, S1P receptors are composed
of seven-transmembrane helices arranged in a structurally conserved bundle with three
loops located in extracellular domains [29]. However, these five subtypes of S1P
receptors have different patterns of expression in various tissues. For example, S1PR1S1PR3 are expressed in almost all the tissues, but S1PR4 and S1PR5 are expressed in
lymphoid and in brain respectively [30].

Coupling S1PR1 with heterotrimeric Gi activates PI3-kinase-Akt/Rac pathway, which
initiates cell migration. S1PR1 coupled with Gi also activates Ras-ERK pathway, which
4

stimulates cell proliferation and moderately activates phospholipase C that initiates Ca 2+
mobilization [31, 32]. In contrast, S1PR2 is coupled with Gi, G12/13, and Gq. S1PR2
coupled with G12/13 activates Rho leading to the inhibition of Rac pathway and cell
migration. S1PR2 coupled with G13 also stimulates adenylate cyclase. In addition to being
coupled with G12/13, S1PR2 activates Gq-PLC-Ca2+ and Gi-Ras-ERK pathways to initiate
release of Ca2+ [33] from intracellular stores to stimulate cell proliferation. S1PR3 also
activates Gi-PI3-kinase-Akt/Rac pathways to stimulate cell migration [34, 35].

S1PR4 is primarily expressed in lymphoid tissue, which is coupled with Gi to mediate
activation of ERK and PLC stimulation and with G12/13 to activate Rho pathway. The
previous study stated that in S1PR4 KO mice, the deficiency of S1PR4 has profound
effect on dendritic cell migration, cytokine secretion and inhibits differentiation of T helper
cells (Th cells) [36]. S1PR5 is mainly expressed in brain and highly expressed in
blood−brain barrier endothelial cells to maintain the integrity of barrier, which can serve
as a novel strategy for treatment of Alzheimer’s or multiple sclerosis [37]. S1PR5 is also
expressed in oligodendrocytes and oligodendrocyte precursor cells (OPCs). The
activation of S1PR5 causes migration of oligodendrocyte progenitor to be inhibited [38].
Based on the interaction of potential functions of S1P receptors, these downstream
signaling pathways provide multiple alternatives to control various diseases.

1.1.4 S1P in kidney diseases
It has been shown that there is a rank order in the expression of S1P receptors in whole
mouse kidney tissue: S1PR1>S1PR3>S1PR2>S1PR4 with no S1PR5 mRNA expression
[39]. Nowadays, a large number of studies have shown that S1P regulates multiple kidney
5

injuries and diseases, such as ischemia-reperfusion injury, diabetic nephropathy,
glomerulonephritis, nephroblastoma and renal fibrosis by participating in cellular signaling
pathways in different cell types. Diabetic nephropathy causes a local S1P increase in rat
kidney. Furthermore, some researchers have demonstrated that activation of S1PR1
protects kidney injuries from early stage of diabetic nephropathy. In addition, activation of
S1PR1 protects kidney from renal-ischemia-reperfusion injury by inhibiting infiltration of
T-cells [39-42]. However, inhibition of S1PR2 attenuates renal injury from ischemiareperfusion injury [43]. Interestingly, S1P can also induce kidney injury by targeting
S1PR2. This increases the expression of cyclooxygenase-2 (COX-2) and prostaglandin
E2 (PGE2) to upregulate kidney mesangial cells migration, which is associated with
glomerular injury [44, 45]. In addition, a previous study has shown that S1P in kidney
mesangial cells is associated with progression of fibrogenesis by activating S1PR2 or
S1PR3 to mimic transforming growth factor beta (TGF-β)/Smad pathway [46, 47]. Our
study was focused on whether SphK1/S1P mediates renal interstitial fibrosis.

1.2 General introduction of fibrosis
Generally, the consequences of chronic kidney disease (CKD) are glomerulosclerosis
and tubulointerstitial fibrosis. The glomerulosclerosis, despite being a disease with its own
entity, causes tubulointerstitial fibrosis by inducing tubular destruction. Thus, renal fibrosis
can also be considered as tubulointerstitial fibrosis since this process features tubular
destruction [48]. Tubulointerstitial fibrosis is normally generated by chronic inflammatory
response. Early stage of fibrogenesis is seen as dysfunction of wound healing. The
stages of wound healing produce provisional extracellular matrix (ECM) to coordinate the
four phases of wound healing: hemostasis, inflammation, proliferation, and remodeling
6

after the damage of endothelial cells or epithelial cells [49]. With duration of injury, ECM
is remodeled and difficult to degrade, which contributes to forming fibrous tissue and
becoming irreversible fibrosis [50]. Renal interstitial fibrosis can be separated into 4
stages: priming, activation, execution and progression. Yet, there is no clear boundary
among these 4 stages and each stage has their specific molecular and cellular
mechanisms [51].

In Chronic kidney disease, the immune cells infiltrate into injury tissues such as
macrophage-innate immune cells and T cells-adaptive immune cells, which to destroys
and removes pathogens and initiate the other four following stages. Priming is the early
stage of fibrotic diseases with infiltration of lymphocytes, monocytes, macrophages,
dendritic cells and mast cells into kidney. Under unresolving situations, immune cells are
triggered to secrete cytokines and further induce kidney fibrogenesis and kidney injury
[52, 53]. Activation is a process that converts normal cells to acquire myofibroblast
phenotypes. Myofibroblasts produce a large amount of extracellular matrix into interstitial
space that are considered to be the primary source of ECM deposition and play a crucial
role in wound healing and remodeling tissue with α-SMA being expressed in
myofibroblasts [54]. Execution is involved in ECM protein synthesis, secretion, invasion
in the interstitial space. During this stage, ECM starts to resist degradation after being
modified. Execution is recognized as an early stage of the fibrosis, which can theoretically
be treated to reverse fibrosis [55]. Progression is the stage for development of
fibrogenesis. This stage involves multiple cellular and molecular mechanisms, which
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contributes to the excessive ECM production and tubular injury and atrophy,
microvascular rarefaction, chronic hypoxia etc. [56, 57].

However, it should be noted that the origins of myofibroblasts remain debated. It has been
shown that there are at least five sources of myofibroblasts such as activation from
interstitial fibroblasts, differentiation from pericytes, recruitment of fibrocytes and the other
mechanisms collectively called epithelial-to-mesenchymal transition (EMT) and
endothelial-to-mesenchymal transition (EndoMT) [58]. It is difficult to track how different
types of cells become myofibroblasts due to lack of cell markers. In conclusion, how
phenotypes of cells are changed into myofibroblasts and the main sources of
myofibroblasts are still a controversial topic.

At present, strong evidence suggests that TGF-β/Smad signaling is a key pathway in
renal fibrosis and participates in the stage of activation and execution because it not only
regulates the production and degradation of ECM but also mediates EMT process [59].
TGF-β is synthesized from inflammatory cells that infiltrate injured tissue. The secreted
TGF-β binds to its receptors that are located on cell membrane in different cell types and
then the downstream molecules Smad2, Smad3 are phosphorylated and activated to
interact with Smad4 forming a complex. The Smad complex will be translocated into
nucleus and regulate the transcription of its target genes such as connective tissue growth
factor (CTGF), fibronectin, type I collagen, vimentin, α-SMA. During this process, the
phenotypic characterizations of the cell are changed into myofibroblasts with vimentin and
α-SMA being expressed in the cells and losing cell-cell adhesion. As a result, the cells
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acquire the ability to migrate and proliferate, which is termed cell dedifferentiation [60,
61]. Myofibroblasts produce extracellular matrix protein such as collagen I and fibronectin.
CTGF is also produced by myofibroblasts to further amplify fibrogenesis [62].

1.2.1 Chronic kidney disease and renal interstitial fibrosis
Chronic kidney disease (CKD) as common conditions of cardiovascular diseases has high
prevalence in America, which is mainly correlated with obesity, old age, diabetes,
hypertension and other cardiovascular diseases [63]. Glomerular filtration rate (GFR) is
used to indicate renal function and is approximately measured by creatinine clearance.
In healthy individuals, the GFR ranges from 90 to 120 mL/min/1.73 m2 in women and 100
to 130 mL/min/1.73 m2 in men. CKD is defined as GFR below 60 mL/min/1.73 m2 along
with urine albumin–creatinine ratio of at least 30 mg/g. There are five stages of CKD.
Stage 1 is defined as GFR above 90 mL/min/1.73 m2. Stage 2 is GFR ranging from 60 to
89 mL/min/1.73 m2. Stage 1 and stage 2 usually have no symptoms to indicate the kidney
damage. Symptoms of CKD start from Stage 3. Stages 3, 4, and 5 are GFR of 30 to 59
mL/min/1.73 m2, 15 to 29 mL/min/1.73 m2, and less than 15 mL/min/1.73 m2, respectively
[64]. Stage 5 is seen as end-stage renal disease (ESRD), which is the kidney failure stage
and requires treatment through dialysis or transplantation [65, 66].

Renal fibrosis, particularly interstitial fibrosis with excessive extracellular matrix (ECM)
deposition in tubulointerstitial space, is recognized as the end-stage in multiple chronic
kidney diseases. The common causes of CKD are obesity, hypertension and diabetes.
Obesity can directly induce CKD or indirectly through outcomes that cause diabetes and
hypertension [67]. Since obesity is usually followed with diabetes, hypertension or other
9

cardiovascular diseases, these diseases contribute to CKD directly, while the
mechanisms of obesity inducing CKD are unclear. Recently, studies have shown that
obesity can be used as an independent risk factor of CKD through inflammation,
lipotoxicity, hemodynamic effects or other unknown mechanisms to induce CKD.
Diabetes and hypertension are independent factors to induce CKD. These lead to
glomerular expansion and cause endothelial dysfunction and hemodynamic changes
through: loss of the glomerular basement membrane electric charge and its thickening, a
decreased number of podocytes, foot-process effacement and mesangial distension [68].
The progressive renal dysfunction triggers the chronic renal injury that finally induces
fibrogenesis.

1.2.2 Renal fibrosis induced by SphK1/ S1P/S1PRs axis
A large amount of accumulating evidence demonstrates that SphK1/S1P/S1PRs axis is
a mediator of fibrogenesis such as cardiac fibrosis, pulmonary fibrosis, renal fibrosis, and
liver fibrosis [69-71]. The extracellular S1P binds to its receptors S1PRs and induces
fibrogenesis by cross communicating with several fibrogenesis pathways. For example,
SphK1/S1P/S1PRs axis induces fibrogenesis by interacting with TGF-β/Smad signaling
pathway intracellularly. After S1P binds to S1PRs, the Smad is also phosphorylated,
which initiates the same downstream TGF-β/Smad signaling to change the phenotypes
of cells into myofibroblasts [72]. In addition, it has been found that S1P also interacts with
platelet-derived growth factor (PDGF) signaling, which is responsible for proliferation of
myofibroblasts and generation of ECM [73, 74]. Besides the direct regulation of fibrosis,
SphK1/S1P/S1PRs axis acts as a mediator of pro-inflammatory response in CKD by
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promoting the infiltration of inflammatory cells into damaged kidney tissue, which is
mediated by the gradients of S1P concentration and S1PRs expression [75].

Although the reports have shown that S1P participates in fibrogenesis in other organs
and kidney tissue, there is no direct evidence showing that SphK1/S1P signaling pathway
mediates renal fibrosis in vivo. Here, the role of SphK1/S1P signaling as a mediator of
renal fibrosis was investigated in C57BL/6 mice and SphK1 KO mice using the model of
unilateral ureteral obstruction (UUO) in the present study.

1.3 Aims of study
The hypothesis to be tested in the present study states that: knockout of SphK1 prevents
kidney damage from UUO due to the inhibition of SphK1/S1P/S1PRs axis signaling with
attenuating fibrosis and morphological injury induced by UUO.
The specific aims are:
1. To determine whether SphK1-S1P signaling pathway mediates renal interstitial
fibrosis.
2. To determine whether the changes in renal fibrotic markers are due to the immune
regulation by knockout of SphK1.
3. To determine whether the morphological injury induced by UUO is attenuated in
SphK1 KO mice.
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CHAPTER TWO
GENERAL METHODS

2.1 Animals, Unilateral Ureteral Obstruction model, and tissue collection
Experiments were performed in 3 month old 25-30g male C57BL/6 mice and SphK1 KO
mice (global knockout) generated on a C57BL/6 background. Mice were purchased from
the Jackson Laboratory. Mice were housed in the Animal Care Facility with 12h light/dark
cycle in a temperature and humidity controlled facility and had free access to food and
water throughout the study. All protocols were approved by the Institutional Animal Care
and Use Committee of the Virginia Commonwealth University.

Unilateral Ureteral Obstruction (UUO) surgery was performed as described previously
[76]. Mice were anesthetized with inhaled isoflurane (2.5%). The midline longitudinal
abdominal incision was performed, which permitted access to the left kidney and ureter.
The left ureter was tied twice below the kidney with surgical silk. The mice were sacrificed
at either 7 days or 14 days and both sides of kidneys were collected. Special attention
was paid to ensure that the point of ligation was identical across animals and that the
damage to the kidneys would be the same in UUO kidneys. A diagram of UUO surgical
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procedure and Day 14 UUO kidney appearance are shown in Figure 2 [77]. All the mice
underwent UUO surgery in left kidney and that the unobstructed contralateral kidney were
used as control. The kidney samples were divided into four groups: Wild type control
group (WT-C), wild type UUO group (WT-UUO), SphK1 KO control group (KO-C), SphK1
KO UUO group (KO-UUO). Each group had 5-6 mice.

14 Days

UUO kidney
Figure 2. Diagram of UUO surgical procedure and Day 14 UUO kidney
appearance.
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2.2 RNA isolation and real time RT-PCR
Total RNA was isolated from mouse kidney tissue using TRIzol reagent (Life Technology,
Rockville, MD, USA) according to the manufacturer's instructions. RNA was quantified
using Shimadzu UV160U UV-Visible Recording Spectrophotometer by 260-280nm
wavelength and 1 μg of RNA was reverse transcribed using the cDNA synthesis kit (cDNA
Synthesis Kit, Bio-Rad, Hercules, CA). The reverse transcribed cDNA products were
amplified using a TaqMan Gene Expression Assays kit (Applied Biosystems). This kit
contains SphK1 primers and FAM dye-labeled probes and had been tested and optimized
for the analysis of mice SphK1 mRNA expression by the manufacturer. A TaqMan gene
expression assays kit for detecting the levels of 18S rRNA was used as an endogenous
control. Data were gathered and analyzed by the same real-time PCR detection system.
The cycle threshold (Ct) values were exported into a Microsoft Excel worksheet for
calculation of gene expression in accordance with the ΔΔCt method. The Ct values were
first normalized with respect to 18S rRNA levels to obtain ΔCt values. The ΔCt values for
SphK1 from the kidney tissue of wild type control group were used as a reference to
calculate ΔΔCt values for all other samples. Relative mRNA levels were expressed as 2
–ΔΔCt.

2.3 Protein preparation and Western Blot
Renal tissues were homogenized with a glass homogenator in ice-cold RIPA lysis buffer
containing: 150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris, protease inhibitor (1:50), pH 8.0. After centrifugation of the homogenate
at 5000g for 5 minutes at 4°C, the supernatant was collected and transferred into a new
microtube. The measurement of protein concentration was performed using Bradford
14

Assay. The dye reagent was prepared by diluting 1 part Dye Reagent Concentrate (BioRad Protein Assay Dye Reagent Concentrate) with 4 parts distilled, deionized (DDI)
water. Diluted dye reagent was filtered to remove particulates. Three serial dilutions of a
protein standard were prepared and Bovine Serum Albumin (BSA) is as standard. The
linear range of the assay for BSA is used as 0.2 to 0.9 mg/ml. Pipet 100 µl of each
standard and sample solution into a clean, dry test tube. Protein solutions were assayed
in duplicate. Add 5.0 ml of diluted dye reagent to each tube and vortex. The mixtures were
incubated at room temperature for at least 5 minutes. Finally, the protein concentration
was determined by the absorbance at 595 nm in disposable polystyrene cuvettes with 1
cm path length by Shimadzu UV160U UV-Visible Recording Spectrophotometer. The
protein samples were frozen in liquid nitrogen and stored at −80°C until used. Western
blot analyses were performed as described previously [78]. In brief, kidney tissue protein
(15 μg) was subjected to 10% SDS-PAGE, transferred onto a PVDF membrane and
blocked by solution with 5% non-fat dry milk in TBS-T. Primary antibodies used in the
present study included GAPDH (rabbit 1:3000, Cell Signaling Technology), collagen I/III
(rabbit 1:2000, Calbiochem), and α-smooth muscle actin (α-SMA) (rabbit 1:2000, Abcam)
and PVDF membrane was incubated in incubation box with primary antibody overnight in
4°C cold room. After the incubation, membrane was washed with TBS 3 times and 10
minutes each time. After washed, PVDF was incubated with horseradish peroxidase
(HRP)

conjugated

secondary

antibody

goat

anti-rabbit

(1:2000,

Santa

Cruz

Biotechnology) for 1 hour and then washed with TBS 3 times and 10 minutes each time.
Remove all TBS from incubation box, and mix 500µl Luminol enhancer solution (Thermo
Fisher Scientific) with 500µl Peroxide solution (Thermo Fisher Scientific) and then
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incubation box was swung by swing bed for 1 minute. Membrane was detected by
Odyssey® Fc Imaging System (LI-COR®) with 2 minutes exposure time. The intensities of
the blots were determined using an imaging analysis program (Image J, free download
from http://rsbweb.nih.gov/ij/). The intensities of target protein α-SMA and collagen I/III
were divided by the intensities of loading control (GAPDH) to obtain the 1st ratio value.
This gave the average target protein value for the WT-C. Then 1st ratio value for each
group was divided by the average target protein value of WT-C to obtain the 2nd ratio
value. The 2nd ratio values were used to normalize the intensity of the target protein band
for each group by averaging the 2nd ratio value for each group.

2.4 Immunohistochemistry
Kidney tissue sections (5 μm) embedded in paraffin were cut and mounted onto
microscope slides. Deparaffinization was induced through heat, tissue cleaning agent,
ethanol and water. To unmask antigen binding sites, slides were boiled in 0.01 M citrate
buffer pH 6.0 for 20 min. Endogenous peroxidase activity was blocked by incubating
slides in 3% H2O2 in 100% MeOH for 30 min. The sections were then incubated at room
temperature for 30 min in 10% Bovine Serum Albumin (BSA) to block nonspecific binding
and incubated overnight at 4 °C in a humid chamber with antibodies against α-SMA
(1:300, Abcam), CD43 M-19 (1:100, Santa Cruz Biotechnology) and CD68 KP-1 (1:100,
Santa Cruz Biotechnology) diluted in PBS-T buffer. Then, after the washing, the slides
were incubated for 30 min at room temperature in a humid chamber with a biotinylated
goat anti-rabbit IgG-B antibody (1:300, Santa Cruz Biotechnology), donkey anti-goat lgGB (1:200, Santa Cruz Biotechnology) or goat anti-mouse lgG-B (1:200, Santa Cruz
Biotechnology) diluted in PBS-T. The slides were subsequently placed in streptavidin16

horseradish peroxidase for 30 min at room temperature in a humid chamber. Finally, the
slides were incubated with 50 μL of diaminobenzidine (BioGenex, San Ramon, CA) as a
substrate, counterstained with hematoxylin (Sigma-Aldrich, Saint Louis, MO),
dehydrated, and fixed with Permount histological mounting medium (Fisher Scientific,
Hampton, NH).

Collagen I/III was stained using picro sirius red. Sirius red is a strong anionic dye, which
react with amino group of lysine and hydroxylysine, and the guanidine groups of arginine
via its sulphonic acid groups. In addition, Picrosirius appeared to be selective for collagen
and however, the reason is unknown [79]. Deparaffinization was the same as
immunohistochemistry. Two solutions were prepared before staining. Solution A is Sirius
red F3B (C.I. 35782) 0.5g with saturated aqueous solution of picric acid 500ml. Solution
B is acidified water containing 5ml acetic acid in 1 liter of distilled water. After
deparaffination, slides were stained with hematoxylin (Sigma-Aldrich, Saint Louis, MO)
for nuclear staining and then solution A for one and half hour. The solution A on the
sections

was

washed

off

with

two

changes

of

solution

B.

Different

with

immunohistochemistry, Sirius Red staining was dehydrated in three changes of 100%
ethanol and fixed with Permount histological mounting medium (Fisher Scientific,
Hampton, NH) also.

The percentage of collagen positive-stained area was calculated using a computer
program Image-Pro Plus 6.0 in 5 microscopic x200 magnification photomicrographs for
each group. Figure 3 describes how to analyze the percentage of positive-stained area:
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Firstly, choose class 1 color shown in red to mark the positive-stained area and then add
another class color shown in yellow to mark the tissue area and press count. Finally, the
program gives us the percentage of each area. However, we tried two methods to analyze
the immunohistochemistry of CD43 and CD68 staining. First method utilized percentage
of positive-stained area in 5 microscopic x200 magnification photomicrographs for each
group, which is also the same as quantification of percentage of collagen-stained area.
Second method as shown in Figure 4, utilized cell counter by Image J program in 5
microscopic x400 magnification (around 100 cells) photomicrographs for each group.
After results were obtained by the two methods, the results were normalized using
Microsoft Excel. The percentage of positive-stained area or percentage of the number of
positive-stained cells were divided by the average of WT-C in each group each time to
get the 1st ratio. The 1st ratio values were used to normalize the percentage of positivestained area or percentage of the number of positive-stained cells by averaging the 1st
ratio values for each group. The results were presented as fold change normalized with
the WT-C.
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A

B

C

Figure 3. Semiquantification of positive staining area from Sirius Red staining
by Image-Pro Plus. A: Choose class 1 color shown in red to mark positive staining
area. B: Choose class 2 color shown in yellow to mark staining of tissue area. C: Press
count and the program will show the percentage of each staining area.
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Figure
4.
Semiquantification
of
positive
cell
staining
from
immunohistochemistry by cell counter in Image J. Type 1 shows the number of
positive staining cells and Type 2 shows the number of normal tissue cells. Percentage
of number of positive staining cells was calculated using the following equation:
Percentage of the number of positive staining cells = Type 1 / (Type 1 + Type 2)
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2.5 Morphological examinations
Glomerular and tubular structures were examined using fixed paraffin-embedded
kidneys, stained with Periodic-Acid Schiff (PAS) stain (SIGMA-ALDRICH PAS staining
system). First, kidney tissue section were deparaffinized and hydrated in deionized water
and then immersed in Periodic Acid Solution for 5 minutes at room temperature. Periodic
Acid Solution was rinsed off in distilled water. Next, slides were immersed in Schiff’s
reagent for 15 minutes at room temperature and then rinsed in running tap water for 5
minutes. Finally, sildes were counterstained in Hematoxylin (Sigma-Aldrich, Saint Louis,
MO) for 90 seconds and then rinsed with tap water for 5 minutes. Sections were
dehydrated and fixed with Permount histological mounting medium (Fisher Scientific,
Hampton, NH). Glomerulus and tubules were scored on a scale of 0–4 depending on the
extent of sclerotic changes. Tubular injury score and glomerular damage index were
scored semiquantitatively by two blinded manners on the minimum 50 cortical fields of
PAS staining using ×400 magnification. The tubular injury is defined as tubular dilatation,
tubular atrophy, sloughing of tubular epithelial cells, or thickening of the tubular basement
membrane and the glomerular damage is defined as segmental or global capillary
collapse with increased matrix deposition. The score was calculated on a scale of 0 to 4,
as follows: 0 = no injury; 1 = 1–25% injured area; 2 = 26–50% injured area; 3 = 51–75%
injured area; 4 >75% injured area [80-82].

2.6 Statistical Analyses
Data are expressed as the mean ± standard error of the mean (SEM). Comparisons
among groups were performed with two-way analysis of variance (ANOVA) followed by
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Dunnett's test to examine the effects of gene deletion and UUO treatment as the
independent factors. P < 0.05 was considered statistically significant.
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CHAPTER THREE
RESULTS

3.1 Attenuated renal interstitial fibrosis induced by UUO in SphK1 KO mice
3.1.1 Enhanced expression of SphK1 mRNA in UUO model
To determine the effect of UUO model and SphK1 KO on the expression of SphK1 mRNA
level, real time RT-PCR was performed on kidney RNA from Day 7 UUO mice. As shown
in Figure 5, the relative expression of SphK1 mRNA was significantly increased in WTUUO compared with WT-C whereas it was barely detectable in KO-UUO compared with
WT-UUO. It is suggested that the UUO induces expression of SphK1 mRNA, which is
prevented in SphK1 KO mice.
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Figure 5. Effect of UUO and SphK1 KO on SphK1 mRNA levels: Real time RT-PCR
analysis showing relative SphK1 mRNA levels in different groups. The final results
were presented as fold change normalized with the WT-C. Data are presented as the
mean ± SEM. * P< 0.05 vs. WT-C (n =3-4), Day 7 UUO.
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3.1.2 No significant difference in the induced expression of fibrotic markers in
Day 7 UUO model between WT and SphK1 KO mice

To detect whether renal fibrosis induced by UUO was attenuated in SphK1 KO mice,
western blot was performed on Day 7 UUO mice first. Figure 6A shows representative
western blot images depicting the levels of collagen I and α-SMA with GAPDH as loading
controls. In summarized intensities as shown in Figures 6B and 6C, levels of α-SMA
were increased in WT-UUO and KO-UUO, and there was statistic significantly attenuated
in KO-UUO compared with WT-UUO. In addition, levels of collagen I were also increased
in WT-UUO and there was statistic significant difference between WT-UUO and KO-UUO.
However, the decrease level of these two fibrotic markers in SphK1 knockout UUO group
compared with WT-UUO is not that much, which drove us to move to Day 14 UUO model.
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Figure 6. Effect of UUO and SphK1 KO on the expression of fibrotic markers in
Day 7 UUO model. A: Representative gel documents showing α-SMA (42 kDa) and
Collagen I (110 kDa) levels. B: Summarized data showing the levels of collagen I
quantitated as a ratio of detected specific protein band vs. GAPDH as loading control
(n=5). C: Summarized data showing the levels of α-SMA quantitated as a ratio of
detected specific protein band vs. GAPDH as loading control (n=5). The final results
were presented as fold change normalized with the WT-C. Data are presented as the
mean ± SEM. * p ＜0.05 vs. WT-C; # p ＜0.05 vs. WT-UUO (n=5), Day 7 UUO.

26

3.1.3 Attenuated expression of fibrotic markers in SphK1 KO mice Day 14 UUO
model

To detect whether renal fibrosis induced by UUO was attenuated in SphK1 KO mice,
western blot was performed on Day 14 UUO mice. Figure 7A shows representative
western blot images depicting the levels of collagen I and α-SMA with GAPDH as loading
controls. In summarized intensities as shown in Figures 7B and 7C, levels of α-SMA and
collagen I were significantly increased in WT-UUO and KO-UUO, whereas the levels of
α-SMA and collagen I were significantly reduced in KO-UUO compared with WT-UUO. It
is suggested that the deletion of SphK1 inhibits fibrogenesis in UUO-induced renal
fibrosis.
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Figure 7. Effect of UUO and SphK1 KO on the expression of fibrotic markers in
Day 14 UUO model. A: Representative gel documents showing α-SMA (42 kDa) and
collagen I (110 kDa) levels. B: Summarized data showing the levels of collagen I
quantitated as a ratio of detected specific protein band vs. GAPDH as loading control
(n=6). C: Summarized data showing the levels of α-SMA quantitated as a ratio of
detected specific protein band vs. GAPDH as loading control (n=6). The final results
were presented as fold change normalized with the WT-C. Data are presented as the
mean ± SEM. * p ＜0.05 vs. WT-C; # p ＜0.05 vs. WT-UUO (n=6), Day 14 UUO.
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3.1.4 Distribution of fibrotic marker α-SMA in renal interstitial space
To

further

detect

renal

interstitial

fibrosis

induced

by

UUO,

we

used

immunohistochemistry for α-SMA staining on Day 7 UUO mice. The positive α-SMA
staining showed a brown color in photomicrographs. As shown in Figure 8, in 100x
magnification of the photomicrographs, the distribution of α-SMA was mainly located in
outer medulla and renal cortical area and that there was almost no staining in inner
medulla; in 200x magnification of photomicrographs, it was more clearly visible that the
distribution of α-SMA in the renal interstitial area. These results suggest that the elevated
expression of α-SMA induced by UUO is located in renal interstitial space.
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Figure 8. Effect of UUO on α-SMA distribution in kidneys. Immunostaining of αSMA was applied on Day 7 UUO mice in WT-UUO and WT-C. The brown color
indicates positive staining in cortex, outer medulla and inner medulla, respectively.
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3.1.5 Distribution of extracellular matrix protein collagen in renal interstitial space
and less collagen staining in SphK1 KO mice

To further detect whether UUO induced renal interstitial fibrosis and knockout of SphK1
inhibited fibrogenesis, we used Sirius Red staining, which is a staining specific to collagen
[83], on Day 14 UUO. As shown in Figure 9A, in 400x magnification of photomicrographs,
the collagen positive staining area in red color and that the collagen staining area was
mainly located in renal cortical interstitial area. Summarized percentage of collagen
staining area is shown in Figure 9B. The collagen staining area was notably more in UUO
groups than in control groups, but much less in KO-UUO than in WT-UUO, which was
consistent with the result of western blot analysis. These data indicate that renal interstitial
fibrosis induced by UUO is attenuated in SphK1 KO mice.
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Figure 9. Effect of UUO and SphK1 KO on collagen distribution by Sirius Red
staining. A: Representative pictures of Sirius-Red-stained kidney sections in cortical
area and the positive collagen staining area showing red color in 400x magnification
of photomicrographs. B: The average percentage of collagen staining was quantified
by analyzing at least five random fields in x200 magnification of photomicrographs per
kidney sample using Image-Pro Plus software. The final results were presented as fold
change normalized with the WT-C. Data are presented as the mean ± SEM. * p ＜0.05
vs. WT-C; # p ＜0.05 vs. WT-UUO (n=5), Day 14 UUO.
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3.2 No significant difference in the infiltration of immune cells between WT-UUO
and KO-UUO

As mentioned above, SphK1-S1P-S1PRs axis is also involved in immune regulation and
that one of the 5 stages of renal fibrosis is infiltration of immune cells into damaged tissue,
which further regulates fibrogenesis. We wanted to detect whether the changes in renal
fibrotic markers between WT-UUO and KO-UUO were due to the immune regulation by
KO of SphK1. CD43, T-cell marker, and CD68, macrophage marker, which indicated
immune response, were stained with immunohistochemistry and the representative
positive staining area was shown brown color in 200x magnification of photomicrographs.
As shown in Figure 10A, the infiltrated immune cells were also mainly located in
interstitial area. Figures 10B and 10C show the normalized average percentage of
CD43- and CD68- positive cells. The positive staining cells were notably more in WTUUO and KO-UUO than those in WT-C and KO-C, but there was no significant difference
between WT-UUO and KO-UUO. Figures 10D and 10E show the normalized average
percentage of CD43- and CD68- positive-stained area. The results were consistent with
normalized average percentage of CD43- and CD68- positive cells. These two methods
of analysis of immune cells infiltration indicate that the difference in renal fibrotic markers
between WT-UUO and KO-UUO may not be due to the possible immune regulation by
SphK1 deletion, rather the direct effect of SphK1 deletion on kidney tissue.
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Figure 10. Effect of UUO and SphK1 KO on the infiltration of immune cells. A:
Representative photomicrographs of immunohistochemistry of kidney sections in
cortical area and the CD43- and CD68- positive cells staining showing brown color in
200x magnification of photomicrographs. B, C: The percentage of CD43- and CD68positive cells was quantified by analyzing at least five random fields in 400x
magnification of photomicrographs per kidney sample with Image J. D, E: The
percentage of CD43- and CD68- positive area was quantified by analyzing at least five
random fields in 200x magnification of photomicrographs per kidney sample with
Image-Pro Plus software. The final results were presented as fold change normalized
with the WT-C. Data are presented as the mean ± SEM. * p ＜0.05 vs. WT-C (n=5),
Day 14 UUO.
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3.3 Attenuated morphological injury induced by UUO in SphK1 KO mice
To detect whether knockout of SphK1 was protective against kidney damage induced by
UUO, the morphological injury was evaluated for glomerular damage index and tubular
injury score on PAS staining. As shown in Figure 11A, glomeruli and tubules in UUO
tissue showed a typical pathological damage profile. There was exhibiting expanded
mesangial matrix with hypercellularity, capillary collapse, and fibrous deposition in the
glomeruli and tubular atrophy and vacuolar degeneration in the tubule epithelia. The two
blinded manners selected minimum 50 renal cortical areas to score tubular injury and
glomerular damage. Summarized tubular injury scores and glomerular damage indices
were shown in Figures 11B and 11C. The injury scores were notably higher in WT-UUO
and KO-UUO than that in WT-C and KO-C respectively, but much lower in KO-UUO than
that in WT-UUO. It is suggested that UUO induces kidney damage through glomerular
damage and tubular injury and compared with wild type mice, knockout of SphK1 protects
kidney in the UUO model.
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Figure 11. Effect of UUO and SphK1 KO on kidney damage. A: Representative
photomicrographs showing tubular and glomerular structures [Periodic Acid-Schiff
(PAS) staining, ×400]. B, C: Summarized tubular injury score and glomerular damage
index by semiquantitation of scores in different groups. The final results were
presented as fold change normalized with the WT-C. Data are presented as the mean
± SEM. * p ＜0.05 vs. WT-C; # p ＜0.05 vs. WT-UUO (n=5), Day 14 UUO.
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CHAPTER FOUR
DISCUSSION AND CONCLUSION

Since there was considerable evidence showing that the SphK1/S1P/S1PRs axis was
involved in various organ fibroses as mentioned in the introduction, the major goals of
the our study were to determine whether SphK1/S1P signaling mediated renal interstitial
fibrosis induced by UUO and if deletion of SphK1 in mice attenuated renal interstitial
fibrosis in vivo study. To induce renal interstitial fibrosis we applied UUO model on male
mice. The reason for selecting male mice is that female mice are resistant to renal
interstitial fibrosis induced by UUO [84]. Furthermore, it has been found that there is a
higher rate for CKD in men than in women due to hormonal regulation between males
and females [85]. If we tested our hypothesis in female mice, it would take more time to
build UUO model than if we used male mice referring to the results from Figure 6 and
Figure 7. Furthermore, we were not sure if SphK1/S1P also participated in hormonal
regulation to further mediate renal interstitial fibrosis. For those reasons, we decided to
choose male mice to test our hypothesis.
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At first, we observed that the expression of SphK1 mRNA was increased 6.1 fold in WTUUO compared with WT-C in Day 7 UUO model. This observation suggested that
upregulated SphK1 might participate in the renal injury. Interestingly, the increased level
of SphK1 was consistent with the findings from a previous study [86], which utilized
SphK1 transgenic (TG) mice that overexpressed SphK1, to detect if SphK1/S1P/S1PRs
mediated fibrogenesis. That study showed that in SphK1 TG mice, the elevated SphK1
increased the production of S1P and then initiated spontaneous generation of interstitial
and perivascular cardiac fibrosis in 3 month old SphK1 TG mice. In addition, deletion of
S1PR3 attenuated cardiac fibrosis in SphK1 TG mice [86]. Our observation of induced
level of SphK1 together with the mentioned findings by others strongly indicate that
SphK1/S1P/S1PRs participates in the renal fibrogenesis in CKD. We then went on
further examine whether the endogenous change of SphK1 in a disease model really
participated in CKD.

Secondly, to detect whether SphK1/S1P signaling mediated renal fibrosis in the UUO
model we identified the levels of fibrotic markers in mice with SphK1 deletion and based
on these markers, we found that renal fibrosis induced by UUO was considerably
attenuated in SphK1 KO mice (Figure 7). As mentioned above, S1P is involved in
different types of fibrosis and one of the previous studies has reported that the
endogenous S1P in liver tissues is increased in cholestasis-induced liver fibrosis [87].
We assumed that UUO model may induce renal fibrosis by elevating level of S1P in
kidney by SphK1. Consistent with a previous study, it has been shown that exogenous
S1P induces fibrogenesis in NRK49F cells in vitro [88]. In that study, the expression of
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α‐SMA, collagen I, collagen IV, tissue inhibitor of metalloproteinase-1 (TIMP1) and
plasminogen activator inhibitor-1 (PAI1) and the activity of cell migration were increased
and the expression of E‐cadherin was decreased in the S1P‐stimulated NRK49F (normal
rat kidney fibroblast cells) cells. In addition, the changing levels of these markers were
related to gradient doses of S1P. That study also showed that renal fibrosis, interstitial
injury and the activity of cell migration were decreased in UUO model by antagonism of
S1PRs with nonselective functional antagonist FTY720 and by inhibiting sphingosine
kinases by DMS, a sphingosine kinase inhibitor, in vivo. It introduced exogenous
compounds to detect the effect of fibrogenesis on UUO model [88]. However, we
detected the effect of endogenous SphK1 on UUO model, which identified the role of
endogenous SphK1 in UUO-induced fibrosis. Our findings led to the conclusion that
SphK1/S1P/S1PRs mediated renal fibrosis in UUO model. Other investigators applied
different days of UUO model depending on the stage of renal fibrosis they studied. Our
data from Day 7 UUO model (Figure 6) did show the statistic difference between WTUUO and SphK1 KO-UUO, but the reduction in the levels of fibrotic markers in Day 7
KO-UUO group is not significant compared with Day 14 UUO model. However, we
manipulated the UUO surgery on Day 7 and Day 14 in different time course. Probably,
the effect of day length of UUO model and genetic interaction on renal fibrosis need to
be investigated in future with identical time course of UUO surgery.

It should be noted that the protein levels of fibrotic markers are still significantly higher
in SphK1 KO UUO group than in non-UUO groups, which indicates that there may be a
compensation of S1P produced by SphK2 in SphK1 KO mice. In addition, it cannot be
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ruled out that there may be other S1P-independent signaling pathways contributing to
fibrogenesis in UUO model. Indeed, our previous studies have shown that prolyl
hydroxylase (PHD)/hypoxia-inducible factor (HIF)-1α signaling mediates fibrogenesis
induced by TGF-β [89]. As a result, there may be interactions between S1P signaling
pathway and other pathways in renal fibrosis, which remains to be clarified.

As we mentioned above, S1P as a bioactive molecule can initiate both extracellular and
intracellular pathways. We assumed that S1P as a mediator of fibrosis may act through
targeting its receptors and receptor-independent signaling to mediate fibrogenesis. One
of the previous studies has found that S1P induces liver fibrosis without binding to S1PRs
[90] . That study has reported that the exogenous TGF-β through increasing expression
of SphK1 induces the elevation of expression of collagen I and collagen III, which cannot
be attenuated in the presence of S1PRs antagonists. It is assumed that SphK1/S1P has
its own intracellular signaling pathway to regulate fibrogenesis [90]. Our study did not
detect which subtypes of receptors were involved in renal interstitial fibrosis induced by
UUO, which is worth investigating in future study.

In addition to measuring the levels of the fibrotic markers by western blot analyses, we
also performed fibrotic markers staining in tissue. In our findings, UUO induced renal
interstitial fibrosis according to the distribution of collagen and α-SMA staining shown in
Figure 8 and Figure 9. We did both Day 7 and Day 14 UUO model to detect distribution
of collagen and α-SMA. Surprisingly, the quantified collagen positive-stained area in Day
14 UUO model was consistent with western blot, whereas the result of α-SMA staining
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in Day 14 UUO showed no significant difference between SphK1 KO UUO and WT-UUO
after normalizing the percentage of positive-stained area. The explanation of this
phenomenon is that in Day 14 UUO model, the tubular dilatation, atrophy and loss of
tubular epithelial cells reached the end stage and the distribution of α-SMA expressed in
mesenchymal cells would be affected by cell loss [91] and further affect the result of
protein staining. Thus, the results of α-SMA from protein levels by western blot and the
distribution by immunostaining were different.

Then we detected the distribution of α-SMA by immunohistochemistry on Day 7 UUO
model, in which the structure of UUO kidney remained relatively intact. We found that αSMA and collagen positive-stained area in UUO kidney was mainly located in cortical
interstitial area. One of the previous studies has reported that HIF-1α not only is the
consequence of renal interstitial fibrosis but also is an inducer to mediate EMT in CKD
and the genetic deletion of HIF-1α attenuates the expression of fibrotic markers such as
α-SMA and connective tissue growth factors (CTGF) [92]. It is suggested that besides
the elevation of HIF-1α as one of the outcomes of fibrosis, HIF-1α is also an important
regulator of fibrogenesis in UUO model. In addition, medulla is more adaptive in hypoxic
condition than cortical area because oxygen tensions are estimated to be about 30 mm
Hg in cortex and 10 mm Hg O2 in medulla [93]. As a consequence, we assumed that
renal cortical area will produce more HIF-1α than medulla in hypoxic condition, which
results in the observation that collagen I and α-SMA are mainly located in cortex
interstitial space. Therefore, we can suppose if there is any link between HIF-1α and
SphK1/S1P signaling to induce interstitial fibrosis as our further study.
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Immune response is involved in the priming stage of the fibrogenesis. The previous study
has shown that the infiltration of T cells that represents adaptive immune response and
infiltration of macrophages that represents innate immune response start after four-hourobstruction. In the first 24 hours, the infiltration of T cells is 10 fold and the infiltration of
macrophages is 30 fold compared with normal condition, respectively [94] and
inflammatory cells progressively infiltrate into kidney tissue for the next 14 days.
Chronically, the cytokines secreted from inflammatory cells trigger infiltration of
inflammatory cells and induce expressions of more chemokines, cytokines and growth
factors, all of which contribute to activation of myofibroblasts and fibrogenesis [95-99].
Interestingly, it also has been reported that the macrophage suppressor mizoribine
attenuates renal interstitial fibrosis induced by UUO [100].

S1P is known to be involved in multiple inflammatory responses such as recruitment of
immune cells into injured tissue. It has been reported that extracellular S1P targets
S1PRs to initiate downstream signaling pathways and leads to the activation of both
STAT3 and NF-κB. STAT3 will further regulate transcription of multiple target genes
involving S1PR1 to enhance S1P-S1PR1 signaling pathway. The activated NF-κB
upregulates the transcription of proinflammatory cytokines and then induces fibrogenesis
[101-104]. Moreover, it is reported that S1P gradients regulate innate and adaptive
immune cells trafficking through S1PRs [105]. Given the role of S1P signaling in the
regulation of immune response and inflammation, we wondered if SphK1 KO altered the
inflammatory process and thereby attenuated fibrosis in UUO. To investigate whether
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SphK1/S1P directly acted on renal cells to participate in renal interstitial fibrosis or
indirectly via modulating inflammation, our study also detected the infiltration of
inflammatory cells in the kidneys with immunohistochemistry (Figure 10). We found that
in SphK1 KO UUO, the increased infiltration of inflammatory cells was not significantly
different from that in WT-UUO. These results indicate that the SphK1/S1P pathway is
probably a direct mediator of renal interstitial fibrosis, rather than immune modulator in
the fibrogenesis of UUO. However, there are different phenotypes of macrophages,
which present different responsibilities. M1 macrophage is seen as the inflammatory
macrophage and M2 is seen as the fibrotic macrophage, so these two phenotypes of
macrophage coexist in injury renal to regulate inflammation-mediated renal cell loss and
fibrogenesis [106]. To further confirm if SphK1/S1P/S1PRS through mediating
inflammatory cells infiltration, the ratio of distribution of different phenotypes
macrophages in UUO model need to be identified in future study. In support of our
findings, another study using nude mice that were athymic animals with deficiency of T
cells found that renal interstitial fibrosis, kidney injury and activity of cell migration
induced by UUO in these immune deficient mice could also be significantly attenuated
by inhibiting S1P signaling [88, 107]. These reports together with our findings in the
present study lead to a conclusion that SphK1/S1P can directly mediate renal interstitial
fibrosis through its extracellular pathway in CKD by bypassing the regulation of immune
response.

Tubular cell death has a close association with progressive renal interstitial fibrosis and
it also has been stated that UUO affects glomerular filtrate rate decreased by 80% and
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the number of glomerulus reduced by 40%. It can be concluded that UUO contributes to
both tubular and glomerular injury [54, 108]. Finally, we detected if UUO and knockout
of SphK1 had effect on kidney damage, which was indicated by tubular injury score and
glomerular damage index that were the outcomes of UUO (Figure 11). As expected,
tubular injury and glomerular damage induced by UUO were attenuated in SphK1 KO
mice. The results demonstrate that knockout of SphK1 could be a new strategy to protect
kidney structure and renal function from CKD.

In summary, the present study revealed a new triggering mechanism of renal interstitial
fibrosis induced by UUO model, which was characterized by upregulation of SphK1
mRNA expression. The deletion of SphK1 attenuated the renal interstitial fibrosis and
kidney damage induced by UUO without significant differences in the infiltration of
inflammatory cells between WT-UUO and KO-UUO. These results may provide new
therapeutic strategies associated with manipulating SphK1/S1P pathway to prevent
renal fibrosis and renal failures initiated by CKD or other cardiovascular diseases such
as diabetes and hypertension.
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